ERNA (Ernexa Therapeutics) FFO


ERNA Ernexa Therapeutics Inc ERNA
30 GF Score
Price $6.30
! 4 Warning Signs
View Full Analysis

What is Ernexa Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.

ERNA
30GF Score
Ernexa Therapeutics Inc ERNA
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ernexa Therapeutics Business Description

Address 1035 Cambridge Street, Suite 18A, Cambridge, MA, USA, 02141
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
30GF Score

Get the complete analysis for ERNA

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.30
Price